Hansoh Pharmaceutical Licenses Novel CDH17-Targeting ADC HS-20110 to Roche in $1.45 Billion Deal

Free attendance, scan to register

October 17,Hansoh Pharma announced that its wholly-owned subsidiaries, Shanghai Hansoh Biomedical Technology Co., Ltd. and Changzhou Hengbang Pharmaceutical Co., Ltd., have signed a licensing agreement with F. Hoffmann-La Roche Ltd.

According to the licensing agreement, Hansoh will grant Roche an exclusive global license (excluding mainland China, Hong Kong, Macao, and Taiwan) for the development, production, and commercialization of HS-20110.Hansoh will receive an upfront payment of $80 million and is eligible to receive milestone payments of up to $1.45 billion (approximately 10.3 billion RMB) based on the development, regulatory approval, and commercialization progress of the product, as well as tiered royalties on future potential product sales.

HS-20110It is a novel antibody-drug conjugate (ADC) independently developed by Hansoh Pharma, consisting of a humanized monoclonal antibody targeting cadherin-17 (CDH17) covalently linked to a topoisomerase inhibitor (TOPOi) payload. This therapy demonstrates broad application potential in the field of solid tumors.

Currently, the drug is undergoing a global Phase I clinical trial in China and the United States for the treatment of colorectal cancer (CRC) and other solid tumors.

By the close of trading, Hansoh Pharma's highest increase in the Hong Kong stock market exceeded 4%.

Globally, the development of CDH17 ADC is still in its early stages, with a total of 9 drugs entering clinical or IND stages, most of which are from Chinese companies, including Hansoh Pharma's HS-20110, Mabwell's 7MW4911, and Lepu Biopharma's CM518D1.

HS-20110 Targets CDH17 (Liver-Intestinal Cadherin), Which Is Expressed Only in the Basolateral Membrane of Intestinal Epithelium in Healthy Tissues but Significantly Overexpressed in More Than 90% of Colorectal Cancers, 50% of Gastric Cancers, Pancreatic Cancers, and Biliary Tract Cancers. It Is Also Closely Associated with Tumor Metastasis and Poor Prognosis, Making It an Ideal Target for Precision Treatment of Gastrointestinal Tumors. Its Highly Specific Expression Provides a Natural "Safety Window" for Drugs, Minimizing Excessive Damage to Normal Tissues.

CDH17 ADC mainly targets refractory solid tumors such as colorectal cancer and gastric cancer. Taking colorectal cancer as an example, there are over 550,000 new cases annually in China, of which about 85% are microsatellite stable (MSS) type, rendering them unresponsive to PD-1 inhibitors. HS-20110 has the potential to address this unmet need. If successfully launched, it is expected to become another breakthrough therapy for gastrointestinal tumors.

Previously, Hansoh had reached two licensing deals in the ADC field with GSK in 2023, with upfront payments of $85 million and $185 million respectively, and maximum milestone payments of $1.485 billion and $1.525 billion respectively.